This Month in Gastroenterology Jan Tack, John M. Carethers  Gastroenterology  Volume 136, Issue 1, Pages 1-4 (January 2009) DOI: 10.1053/j.gastro.2008.11.061 Copyright © 2009 AGA Institute Terms and Conditions

Figure 1 Overall survival rates in type I (gray line) and type II (black line) refractory celiac disease. The 5-year survival rate was 93 % in type I versus 44% in type II disease. Gastroenterology 2009 136, 1-4DOI: (10.1053/j.gastro.2008.11.061) Copyright © 2009 AGA Institute Terms and Conditions

Figure 2 Number of painful days per month during treatment with placebo or antioxidant supplementation. Gastroenterology 2009 136, 1-4DOI: (10.1053/j.gastro.2008.11.061) Copyright © 2009 AGA Institute Terms and Conditions

Figure 3 (A) Complexation of the polymeric binder P(HEMA-co-SS) with gliadin. (B) SDS-PAGE of albumin, ovalbumin, α-gliadin, and lysozyme (40 mg/mL) incubated with (+) or without (−) P(HEMA-co-SS) (25 kDa; protein/polymer weight ratio of 1:2) at pH 6.8 and 37°C. Gastroenterology 2009 136, 1-4DOI: (10.1053/j.gastro.2008.11.061) Copyright © 2009 AGA Institute Terms and Conditions

Figure 4 Exocrine pancreas involution in aged c-MycP−/− animals. (A, B) Hematoxylin and eosin staining reveals the involution of c-MycP−/− exocrine pancreas at 10 months, which is replaced with adipose tissue, whereas islets (arrows) remain unaffected (B). Original magnification, ×40. (C) Pancreas weight is still reduced by 31% despite the adipose replacement (P < .001). (D) Pancreatic ductal network of c-MycP−/−, estimated as the ductal (DBA+) area relative to the endocrine (Synaptophysin+) area is reduced by 70% (P < 0.001). (E) Total c-MycP−/− pancreatic amylase activity is about 50% of that of control mice (P < .001). Gastroenterology 2009 136, 1-4DOI: (10.1053/j.gastro.2008.11.061) Copyright © 2009 AGA Institute Terms and Conditions